Key Data Files for this Active Pharmaceutical Ingredient:

Drug Master Files, 21 CFR, and other industry portals Patent/Exclusivity data file Drug Approval Drug Safety Freedom of Information Federal Register pages Pharma Companies Pharmacopeial Information Preferred API Supplier (Clients Only)

FDA Approval Activities for this Drug… GlucaGen [glucagon (rDNA origin) for Injection, Novo Nordisk NDA 20-918/S3 7/11/02 7/15/02 GlucaGen [glucagon (rDNA origin) for injection, SC, IM, or IV injection], Novo Nordisk NDA 20-918 6/22/98 6/24/98 6/24/98 GlucaGen Indications: Treatment of hypoglycemia, and Use as a diagnostic aid. Glucagon (rDNA origin) for Injection, Eli Lilly NDA 20-928 9/11/98 9/17/98 9/17/98 3/16/99 Glucagon Indications:1) The treatment of severe hypoglycemia, and 2) Use as a diagnostic aid in the radiologic examination of the stomach, duodenum, small bowel, and colon when diminished intestinal motility would be advantageous. (Patient Information- 9/24/98) Glucagon (rDNA origin) for Injection, RxEli Lilly GlucaGen [glucagon (rDNA origin) Injection, Novo Nordisk Pharmaceuticals   For the latest approval information, locate this drug using this index.